Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Increased prevalence of Chlamydophila pneumoniae but not Epstein–Barr antibodies in essential hypertensives

Journal of Human Hypertension volume 17, pages 21–27 (2003)Cite this article

Abstract

Conflicting data exist regarding the relationship between Chlamydophila pneunoniae (C. pneumoniae) and hypertension. In this study, both C. pneumoniae IgG andIgA titresand Epstein–Barr virus antibody levels were measured in 146 sustained hypertensives defined by 24 h ambulatory blood pressure monitoring (ABPM) and 54 normotensives. C. pneumoniae antibodies were measured by microimmunofluorescence test. IgG⩾80 and IgA⩾40 were defined as elevated antibody titres. Epstein–Barr antibodies were measured in order to investigate whether a possible association exists between hypertension and other, similarly widespread in the general population, intracellular microorganisms. All participants underwent casual blood pressure (BP) readings and 24 h ABPM. Subjects having mean 24 h systolic/diastolic ambulatory BP>125/80 mmHg, with or without antihypertensive medication were defined as hypertensives. Controls were free of any history or clinical evidence of hypertension, cardiovascular or pulmonary disease. Of the total participants, 77 hypertensives (52.7%) and 10 normotensives (18.5%) had IgA titres ⩾40 (crosstabs P<0.000), whereas 76 hypertensives (52.1%) and 15 normotensives (27.8%) had IgG titres ⩾80, (crosstabs P<0.002). No difference was found in Epstein–Barr antibodies, between hypertensives and normotensives. In conclusion, C. pneumoniae, but not Epstein–Barr, antibody levels were found significantly higher in sustained hypertensives, suggesting high frequency of chronic C. pneumoniae, infections in this specific group of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Grayston JT . Infection caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 5: 757–763.

    Article  Google Scholar 

  2. Thom DH et al. Association of prior infection with C. pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68–72.

    Article  CAS  Google Scholar 

  3. Mendall MA et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121–128.

    Article  CAS  Google Scholar 

  4. Saikku P et al. Serological evidence of an association of a novel chlamydia TWAR with chronic coronary heart disease and acute myocardial infarctions. Lancet 1988; 2: 983–986.

    Article  CAS  Google Scholar 

  5. Melnick LS et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study investigators. Am J Med 1993; 95: 499–504.

    Article  CAS  Google Scholar 

  6. Grayston JT et al. Chlamydia pneumoniae (TWAR) in the atherosclerosis of carotid artery. Circulation 1995; 92: 3397–3400.

    Article  CAS  Google Scholar 

  7. Wimmer MLJ, Sandmann SR, Saikku P, Haberl RL . Association of chlamydial infections with cerebrovascular disease. Stroke 1996; 67: 2207–2210.

    Article  Google Scholar 

  8. Tavendale R et al. Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events; the Scottish Heart Health Study Cohort. Eur Heart J 2002; 23: 301–307.

    Article  CAS  Google Scholar 

  9. Hirashima Y et al. Chlamydia pneumoniae infection is not involved in carotid artery stenosis. Artherosclerosis 2002; 163: 165–168.

    Article  CAS  Google Scholar 

  10. Johnson W, Moses J, Kipshidze N . Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction. Cardiovasc Radiat Med 2001; 2: 221

    Article  CAS  Google Scholar 

  11. Altman R, Rouvier J, Scazziota A, Gonzalez C . No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease. Inflammation 2002; 26: 25–30.

    Article  Google Scholar 

  12. Danesh J et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 2002; 23: 371–375.

    Article  CAS  Google Scholar 

  13. Cook PJ et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589–594.

    Article  CAS  Google Scholar 

  14. Nishimura M et al. Inverse association of Chla-mydia pneumoniae infection with high blood pressure in Japanese adults. Am J Hypertens 2001; 14: 20–26.

    Article  CAS  Google Scholar 

  15. Manning G, Rushton L, Millar-Craig MW . Clinical implications of white coat hypertension: an ambulatory blood pressure monitoring study. J Hum Hypertens 1999; 13: 817–822.

    Article  CAS  Google Scholar 

  16. Pose-Reino A et al. Clinical implications of white coat hypertension. Blood Press 1996; 5: 264–273.

    Article  CAS  Google Scholar 

  17. 1999 World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

  18. Zakopoulos NA et al. Reproducibility of ambulatory blood pressure measurements in essential hypertension. Blood Press Monit 2001; 6: 41–45.

    Article  CAS  Google Scholar 

  19. Galimberti L . Uso adeguato ed inadeguato degli alcoolici in patologie e problemi connessi all' uso inadeguato degli alcoolici. Giunta Regionale Venice 1982; 10: 73–89.

    Google Scholar 

  20. Verdecchia P, Staessen JA, White WB, Imai Y, O’Brien ET . Properly defining white-coat hypertension. Eur Heart J 2000; 23: 106–109.

    Article  Google Scholar 

  21. Jauhianinen T et al. Interference of immunoglobulin G antibodies in IgA antibody determinations for C. pneumoniae by microimmunofluorecence test. J Clin Microbiol 1994; 32: 839–840.

    Google Scholar 

  22. Bauer G . The rational basis for efficient Epstein–Barr virus (EBV) serology. Review. Clin Lab 1995; 41: 623–634.

    CAS  Google Scholar 

  23. Saikku P . The epidemiology and significance of Chla-mydia pneumoniae. J Infect 1992; 25 (Suppl 1) 27–34.

    Article  Google Scholar 

  24. Kutlin A et al. Evaluation of Chalamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chalamydia pneumoniae infection. Clin Diag Lab Immunol 1997; 4: 213–216.

    CAS  Google Scholar 

  25. Hughes C et al. Possible nosocomial transmission of psittacosis. Infect Control Hosp Epidemiol 1997; 18: 165–168.

    Article  CAS  Google Scholar 

  26. Ossewaarde JM, de Vries A, Bestebroer T, Angulo AF . Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chalamydia sp. strains. Appl Environ Microbiol 1996; 62: 328–331.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Verkooyen RP et al. Widely used commercially available Chlamydia pneumoniae antigen contaminated with mycoplasma. J Med Microbiol 1997; 46: 419–424.

    Article  CAS  Google Scholar 

  28. Maass M et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998; 140 (Suppl 1) S25–S30.

    Article  CAS  Google Scholar 

  29. Del Piano M, Sessa R, Di Pietro M . Chlamydia pneumoniae infection and atherosclerotic coronary disease: a new possible etiopathogenic association. In: Starling A (ed). Proceedings of the Third meeting of the European society for Chlamydia Research 1995 p225

  30. Markus S et al. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832–837.

    Article  CAS  Google Scholar 

  31. Saikku P . Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J 1999; 138 (Suppl 2) S500–S503.

    Article  CAS  Google Scholar 

  32. Saikku P et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273–277.

    Article  CAS  Google Scholar 

  33. Cook PJ, Davies P, Wise R, Honeybourne D . Chlamydia pneumoniae infection and ethnic origin. Ethn Health 1998; 3: 237–246.

    Article  CAS  Google Scholar 

  34. Pristipino C et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101 (10)1102–1108.

    Article  CAS  Google Scholar 

  35. Verdecchia P, Porcellati C, Schillaci G . Ambulatory blood pressure. An independent predictor of prognosis in essiential hypertension. Hypertension 1994; 24: 793–801.

    Article  CAS  Google Scholar 

  36. Yamashiroya M, Ghosh L, Yang R, Robertson L . Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988; 130 (1) 71–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Benditt PE, Barrett T, McDougall KJ . Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983; 80: 6389–6389.

    Article  Google Scholar 

  38. Musiani M et al. Antibody patterns against Cytomegalovirus and Epstein–Barr virus in human atherosclerosis. Microbiologica 1990; 13: 35–41.

    CAS  PubMed  Google Scholar 

  39. Alexander ER, Harrison HR . Chlamydial infections. In: Evans AS, Brachman PS (eds). Bacterial Infections of Humans: Epidemiology and Control, 2nd edn. Plenum Medical Book Co: New York. 1991, pp 179–206.

    Chapter  Google Scholar 

  40. Leinonen M, Saikku P . Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999; 138 (Supp 1): S504–S506.

    Article  CAS  Google Scholar 

  41. Chapleau WM et al. Structural versus functional modulation of the arterial baroreflex. Hypertension 1995; 26: 341–347.

    Article  CAS  Google Scholar 

  42. Vlachakis ND, Mendlowitz M, DGuia D, DGusman D . Diminished baroreceptors sensitivity in elderly hypertensives. Possible role of atherosclerosis. Atherosclerosis 1976; 24: 243–249.

    Article  CAS  Google Scholar 

  43. Sanderson JE, Billingham JD, Floras J . Baroreceptor function in the hypertensive black African. Clin Exp Hypertens A 1983; 5: 339–351.

    CAS  PubMed  Google Scholar 

  44. Li Z, Mao ZH, Abboud M, Chapleau WM . Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res 1996; 79: 802–811.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, National and Kapodistrial University, Athens, Greece

    V Ch Pitiriga, V Th Kotsis, M-E K Alexandrou, V D Petrocheilou-Paschou, N Kokolakis, R N Zakopoulou & N A Zakopoulos

Authors
  1. V Ch Pitiriga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Th Kotsis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M-E K Alexandrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V D Petrocheilou-Paschou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Kokolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R N Zakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N A Zakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N A Zakopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pitiriga, V., Kotsis, V., Alexandrou, ME. et al. Increased prevalence of Chlamydophila pneumoniae but not Epstein–Barr antibodies in essential hypertensives. J Hum Hypertens 17, 21–27 (2003). https://doi.org/10.1038/sj.jhh.1001501

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001501

Keywords

This article is cited by

Search

Advanced search

Quick links